GRIN Therapeutics Introduces Breakthrough Radiprodil in GRIN-Related Neurodevelopmental Disorder
GRIN Therapeutics has introduced radiprodil, an investigational treatment for seizures associated with GRIN-related neurodevelopmental disorder caused by gain-of-function (GoF) mutations.
Radiprodil is designed to selectively modulate GluN2B, a receptor subtype linked to neurodevelopmental disorders. Preclinical studies have demonstrated its potential antiseizure effects, particularly in conditions with enhanced GluN2B NMDA transmission due to GoF mutations.
GRIN-related neurodevelopmental disorder is a group of rare genetic conditions caused by mutations in GRIN genes. Symptoms can appear in infancy, though diagnosis is often confirmed later when developmental delays become evident.
Affected individuals may experience intellectual disabilities, epilepsy, movement disorders, feeding difficulties, and behavioural challenges. At present, no approved treatments are available for this condition.
Existing therapies for GRIN-related neurodevelopmental disorder primarily focus on symptom management, with no approved treatments targeting the underlying disease mechanism.
However, these approaches do not directly address the neurological dysfunction caused by gain-of-function (GoF) mutations in GRIN genes.
Additionally, many available or experimental treatments do not specifically modulate NMDA receptor activity, which plays a key role in seizure development and other neurodevelopmental challenges.
Radiprodil stands out as a selective negative allosteric modulator of the NR2B (GluN2B) receptor subtype and has now received Breakthrough Therapy designation from the FDA.
